Early Feasibility of 'Pivot Extend' for Tricuspid Regurgitation Treatment

ClinicalTrials.gov ID

NCT06877520

Lead Sponsor

Tau-MEDICAL Co., Ltd.INDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

7Estimated

Last Update Posted

Apr 11, 2025Actual

Start Date

May 2025Estimated

Primary Completion Date

May 2026Estimated

Completion Date

Dec 2026Estimated

Official Title

Early Feasibility Study (EFS) of the 'Pivot Extend' in Treatment for Tricuspid Regurgitation (SPACER Study)

Brief Summary

This clinical trial aims to evaluate the safety and demonstrate the efficacy of treatment to improve tricuspid regurgitation (TR) symptoms in patients with severe and clinically symptomatic TR through long-term implantation of an investigational medical device.

1. Determine the safety of long-term implantation of the investigational medical device "Pivot Extend" by monitoring for MACEs associated with the investigational medical device or procedure that may occur with long-term associated with the investigational medical device or procedure that may occur with long-term implantation.
2. Device success, procedural success, and clinical outcomes of long-term implantation of the investigational medical device "Pivot Extend" will be monitored.

• Tricuspid Regurgitation (TR)

• Pivot Extend Tricuspid Regurgitation Spacer Device

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Adults 18 years of age or older at the time of screening
2. Those with symptoms despite medical therapy (OMT, diuretics/medications) for TR for at least 1 month at screening
3. Those who meet the criteria of severe (3+) or worse on the TR grade classification table on echocardiography performed at the screening visit
4. Those with clinical symptoms of New York Heart Association (NYHA) class 2 or worse
5. Those deemed suitable for percutaneous valve intervention by a Heart Team that includes at least one cardiologist, one cardiac surgeon and one anesthesiologist.
6. Those who have voluntarily decided to participate in this clinical trial and have provided written informed consent
7. Those who can understand and follow the investigator's instructions and are able to participate for the entire duration of the study

Exclusion Criteria:

1. Those with blood clots, emboli, masses, or growths in the vascular system of the heart or lungs on an echocardiogram and cardiac CT scan performed at the screening visit
2. Those with uncorrected blood clotting disorders based on hemanalysis performed at the screening visit
3. Those who are unable to use anticoagulant agents (NOAC ex.Xarelto)
4. Those who have had major bleeding (not including minor bleeding, such as a nosebleed that can be hemostasized) treated with anticoagulants prior to participation in this clinical trial
5. Those with severe anemia (hemoglobin ≦10g/dL) that requires hospitalization
6. Those who have an implanted device such as an implantable cardioverter defibrillator (ICD) or pacemaker prior to participation in this clinical trial
7. Those whose anatomy, in the opinion of the investigator, is not suitable for implantation of an investigational medical device based on echocardiogram and cardiac CT scan performed at the screening visit
8. Those who require surgery or interventional procedures (coronary artery bypass graft (CABG) or surgery for atrial septal defect (ASD)) based on an echocardiogram performed at the screening visit
9. Those with a platelet count of 80,000/uL or less based on hemanalysis performed at the screening visit
10. Patients with pulmonary arterial hypertension with a TR Vmax greater than 3.5 m/s on echocardiography performed at the screening visit or a pulmonary vascular resistance of more than 3 Wood Units on right heart catheterization
11. Those with a left ventricular ejection fraction (LVEF) of less than 50% on echocardiogram performed at the screening visit
12. Those who have had active gastrointestinal bleeding or a digestive procedure within 3 months prior to participation in this study (those with the potential for gastrointestinal bleeding)
13. Those with a history of cerebrovascular accident (CVA) or transient ischemic attacks (TIA) within 30 days prior to participation in this clinical trial
14. Those with a history of myocardial infarction (MI) within 30 days prior to participation in this study
15. Those with active endocarditis requiring antibiotic treatment
16. Those with malignancies with end-stage renal failure requiring hemodialysis and other chronic conditions who have a life expectancy of less than one year
17. Those with moderate or severe aortic, pulmonary artery, or mitral stenosis on echocardiogram performed at the screening visit
18. Those with moderate or worse mitral valve regurgitation or severe aortic valve regurgitation on the echocardiogram performed at the screening visit
19. Those with calcification of the tricuspid valve lobes affecting the procedure on an echocardiogram performed at the screening visit
20. Those who have participated in another clinical trial within 30 days prior to participation in this clinical trial
21. Pregnant or nursing women, or women planning to become pregnant during the clinical trial period
22. Women of childbearing potential who are not using a medically accepted birth control method
23. Those with a coexisting condition, which most likely limits the participant´s life expectancy to less than one year.
24. Those with a preexisting pulmonary valve prosthesis or RV to PA conduit.
25. Those with clinical findings other than the above that, in the opinion of the investigator, are medically inappropriate for this clinical trial

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Tau-MEDICAL Co., Ltd.INDUSTRY

• Early Phase Study Using the 'Pivot Extend' System as a Treatment for Patients With Tricuspid Regurgitation

  NCT07172477

  RecruitingInterventionalNot ApplicableUpdated Dec 9, 2025
• Acute Safety and Efficacy of the Pivot Bridge System for Functional Tricuspid Regurgitation

  NCT07385625

  RecruitingInterventionalNot ApplicableUpdated Feb 4, 2026
• The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat FTR

  NCT05854095

  CompletedInterventionalNot ApplicableUpdated Feb 8, 2024
• Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of FTR

  NCT05648838

  CompletedInterventionalNot ApplicableUpdated Apr 16, 2025
• Safety and Feasibility Study: Transcatheter Valve Repair in Severe Symptomatic Functional Tricuspid Regurgitation

  NCT07140562

  RecruitingInterventionalNot ApplicableUpdated Aug 24, 2025
• The SPACER Trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System

  NCT02787408

  CompletedInterventionalNot ApplicableUpdated Oct 25, 2022

info@tbhc.ge+995 32 250 81 06